GIMV
Investor profile
Investment firmVenture capital
GIMV has backed 49 European tech companies across 70 funding rounds between 2005 and 2026, joining rounds totalling €1.3B. Most active in Healthtech and Software. Data as of 4 Nov 2026.
Also recorded as: Gimv
Deals
70
distinct rounds
Companies
49
backed
Active span
2005–2026
22 yrs
Total round €
€1.3B
sum of rounds joined
Deals by year
distinct rounds / yearGIMV — deals by year — interactive chart.
Data table
| GIMV — deals by year | |
|---|---|
| 2005 | 2 |
| 2006 | 5 |
| 2007 | 3 |
| 2008 | 2 |
| 2009 | 2 |
| 2010 | 7 |
| 2011 | 5 |
| 2012 | 6 |
| 2013 | 3 |
| 2014 | 1 |
| 2015 | 3 |
| 2016 | 8 |
| 2017 | 6 |
| 2018 | 1 |
| 2019 | 2 |
| 2021 | 3 |
| 2022 | 2 |
| 2023 | 4 |
| 2024 | 2 |
| 2025 | 2 |
| 2026 | 1 |
Top sectors
by dealsGIMV — top sectors — interactive chart.
Data table
| GIMV — top sectors | |
|---|---|
| Healthtech | 23 |
| Software | 10 |
| Cleantech | 5 |
| Telecom | 5 |
| Semiconductors | 5 |
| Agritech | 4 |
| Cybersecurity | 4 |
| Marketing | 3 |
| Consumer | 3 |
| Media | 2 |
Stages
by dealsGIMV — stages — interactive chart.
Data table
| GIMV — stages | |
|---|---|
| Series B | 13 |
| Series A | 12 |
| Early VC | 11 |
| Series C | 11 |
| Other | 9 |
| Growth/Late | 8 |
| Seed | 3 |
| Series D+ | 3 |
Countries
by dealsGIMV — countries — interactive chart.
Data table
| GIMV — countries | |
|---|---|
| Belgium | 23 |
| France | 14 |
| Netherlands | 10 |
| Germany | 7 |
| Switzerland | 7 |
| Ireland | 3 |
| UK | 3 |
| Luxembourg | 1 |
| Poland | 1 |
| Spain | 1 |
Co-investment network
shared roundsCo-investment network — interactive chart.
Hover a node for shared-deal counts; click a co-investor to open its profile.
Best viewed on a larger screen.
Frequent co-investors
shared rounds- Sofinnova Partners6
- BioMedPartners4
- Gilde Healthcare4
- LSP4
- PMV4
- Amadeus Capital Partners3
- Andera Partners3
- Groupe Siparex3
- IDInvest Partners3
- INKEF Capital3
- Iris Capital3
- Lightstone Ventures3
- Medtronic3
- Novo Holdings3
- Pfizer Ventures3
- Qbic3
- Seventure Partners3
- VIB3
- Agri Investment Fund2
- Boehringer Ingelheim Venture Fund2
- Draper Esprit2
- EQT Life Sciences2
- Forbion2
- Hummingbird Ventures2
- Intel Capital2
Portfolio
top 30 by total round €| Company | Country | Rounds | Total € |
|---|---|---|---|
| Fire1 | Ireland | 3 | €179M |
| Precirix | Belgium | 1 | €80M |
| Immunos Therapeutics | Switzerland | 2 | €78M |
| Complement Therapeutics | Germany | 1 | €72M |
| Inside Secure | France | 4 | €69M |
| Agrosavfe | Belgium | 4 | €59M |
| Spineart | Switzerland | 2 | €57M |
| Endosense | Switzerland | 2 | €56M |
| Exciva | Germany | 1 | €51M |
| Anjarium Biosciences | Switzerland | 1 | €51M |
| Breath Therapeutics | Germany | 1 | €44M |
| iSTAR Medical | Belgium | 1 | €40M |
| Camel-IDS | Belgium | 1 | €37M |
| Biom'Up | France | 1 | €31M |
| Onera Health | Netherlands | 1 | €30M |
| Itineris | Belgium | 3 | €27M |
| Onward | Netherlands | 1 | €27M |
| G-Therapeutics | Netherlands | 1 | €26M |
| Teads | France | 1 | €23M |
| Clear2Pay | Belgium | 2 | €22M |
| GreenPeak | Netherlands | 2 | €22M |
| Imcheck Therapeutics | France | 1 | €20M |
| Liquavista | Netherlands | 2 | €19M |
| Topas Therapeutics | Germany | 1 | €18M |
| Ebuzzing | UK | 1 | €18M |
| MarcoVasco (Planetveo) | France | 1 | €15M |
| Movea | France | 2 | €14M |
| McPhy | France | 1 | €14M |
| Equipe Zorgbedrijven | Netherlands | 1 | €13M |
| Real Impact Analytics | Luxembourg | 1 | €12M |
Biggest deals
top 10 by amount| Company | Stage | Amount | Date |
|---|---|---|---|
| Fire1 | Other | €115M | 2025-01 |
| Precirix | Series B | €80M | 2022-03 |
| Complement Therapeutics | Series A | €72M | 2023-04 |
| Immunos Therapeutics | Series B | €68M | 2022-06 |
| Exciva | Series B | €51M | 2026-01 |
| Anjarium Biosciences | Series A | €51M | 2021-09 |
| Breath Therapeutics | Series A | €44M | 2017-03 |
| Fire1 | Series C | €40M | 2018-01 |
| iSTAR Medical | Series C | €40M | 2019-07 |
| Camel-IDS | Series A | €37M | 2018-11 |